Development of SLIC, a methodology for synthetic lethal screening in the CNS
Development of SLIC, a methodology for synthetic lethal screening in the CNS
批准号:
9097820
负责人:
Myriam Heiman
金额:
$35.4万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-09-25 至 2017-06-30
关键词:
Affinity ChromatographyAgeAnimal ModelAnimalsBar CodesBrainCaenorhabditis elegansCell DeathCell physiologyCellsCellular biologyCorpus striatum structureDNA SequenceDependencyDevelopmentDiseaseDisease modelDropsEnhancersEnvironmentEtiologyGenerationsGenesGenetic ScreeningGenomeGoalsHealthHumanHuntington DiseaseHuntington geneIn VitroIndividualInjection of therapeutic agentInstitutesLeadLentivirus VectorLibrariesMethodologyModelingMolecularMolecular ProfilingMusMutationNatureNeuraxisNeurodegenerative DisordersNeuronsNeurosciences ResearchOperative Surgical ProceduresPathway interactionsPatientsPredispositionRNA InterferenceResearchResearch PersonnelRibosomesSaccharomyces cerevisiaeSequence AnalysisSubfamily lentivirinaeTherapeuticToxic effectTranslatingVertebratesViralWild Type MouseWorkcell typecostgene discoverygenetic manipulationgenome-widegenome-wide analysisin vivoknock-downmeetingsmouse modelmutantnext generation sequencingnoveloverexpressionscreeningsequencing platformsmall hairpin RNAsuccesstherapeutic target
中文摘要
描述(由申请人提供):挑战:鉴于大多数主要疾病缺乏有效的治疗方法,需要在神经退行性疾病研究领域提出新的假设。在简单的模式生物中,无偏倚的全基因组遗传筛选被用于以无偏倚的方式产生新的假设。合成致死基因筛选是一种基因筛选,在这种基因筛选中,一个没有毒性或毒性很小的突变通过额外的基因操作增强为现在有毒性的突变。因此,“合成致死”筛选被用来揭示与毒性突变基因相互作用的基因和途径。目前,由于成本过高和需要的动物数量,在小鼠身上进行这种基因筛选是不可行的。我们提出了一种合成致死性中枢神经系统(CNS)的策略,我们称之为SLIC。影响:使用我们的SLIC方法在小鼠中枢神经系统中进行无偏倚的全基因组筛选的能力将允许对神经退行性疾病的病因产生新的假设。潜在的影响将是探索潜在治疗靶点的无数新途径。一旦开发出来,我们的SLIC方法可以被其他研究人员应用于任何遗传诱导疾病的研究。方法:我们认为在大多数神经退行性疾病的小鼠模型中发现缺乏细胞死亡是一个独特的机会。我们建议在小鼠脑中进行合成致死筛选,以增强神经退行性疾病相关突变的毒性。SLIC合成致死筛选将结合使用i)慢竞争shRNA或诱导的条形码过表达文库;ii)将这些文库注入小鼠疾病模型和野生型幼崽的立体定位中枢神经系统;iii)孵育注射文库,使增强毒性的shrna或过表达基因导致细胞死亡;iv)对所有存活细胞中剩余的shrna和条形码过表达构建体进行测序和分析,以确定哪些构建体导致细胞死亡,从而“退出”病毒表征。我们将围绕以下具体目标开展工作:目标1。开发一种方法,允许在小鼠中枢神经系统(CNS)中进行合成致死筛选;目标2。使用Aim 1中开发的方法识别体内亨廷顿蛋白毒性增强因子
英文摘要
DESCRIPTION (provided by applicant): Challenge: New hypotheses in the neurodegenerative disease research field are needed, given the lack of effective therapeutics for most of the major diseases. In simple model organisms, unbiased, genome-wide genetic screens are used to generate new hypotheses in an unbiased way. Synthetic lethal genetic screens are genetic screens in which a mutation that has no or little toxicity is enhanced by an additional genetic manipulation into a mutation that now does. Thus 'synthetic lethal' screens are used to reveal genes and pathways that genetically interact with toxic mutations. Currently it is not feasible to conduct such genetic screens in mice, due to prohibitive cost and numbers of animals needed. We propose to develop a strategy for synthetic lethal in the central nervous system (CNS), which we term SLIC. Impact: The ability to perform unbiased, genome-wide screens in the mouse CNS with our SLIC methodology would allow for the generation of novel hypotheses regarding the etiology of neurodegenerative disease. The potential impact would be myriad new avenues to explore potential therapeutic targets. Once developed, our SLIC methodology could be applied by other researchers to the study of any genetically-induced disease. Approach: We view the lack of cell death found in most mouse models of neurodegenerative disease as a unique opportunity. We propose to conduct synthetic lethal screens in mouse brain, to enhance the toxicity of neurodegenerative disease-associated mutations. SLIC synthetic lethal screens will be conducted by combining the use of i) lentirival shRNA or inducible, barcoded overexpression libraries; ii) stereotaxic CNS injection of these libraries into mouse models of disease and wild-type littermates; iii) incubation of injected libraries, such that shRNAs or overexpressed genes that enhance toxicity will lead to cell death; iv) sequencing and analysis of the remaining shRNAs and barcoded overexpression constructs in all surviving cells, in order to determine which constructs have led to cell death, and thus 'drop out' of viral representation. Our work will be conducted along the following specific aims: Aim 1. To develop a methodology that allows for synthetic lethal screens in the mouse central nervous system (CNS); Aim 2. To identify, using the methodology developed in Aim 1, enhancers of Huntingtin toxicity in vivo
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
Synthetic lethal screening in the mammalian central nervous system identifies Gpx6 as a modulator of Huntington's disease.
哺乳动物中枢神经系统的综合致死筛选确定 Gpx6 是亨廷顿病的调节剂。
DOI:
10.1073/pnas.1417231112
发表时间:
2015
期刊:
Proceedings of the National Academy of Sciences of the United States of America
影响因子:
11.1
作者:
[Shema,Reut, Kulicke,Ruth, Cowley,GlennS, Stein,Rachael, Root,DavidE, Heiman,Myriam]
通讯作者:
Heiman,Myriam
Molecular Mechanisms Underlying Cell Type-Specific Vulnerability in Huntington’s Disease
-
批准号:10457670
-
项目类别:
-
资助金额:$54.29万
-
财政年份:2022
-
负责人:Myriam Heiman
-
依托单位:
Molecular Mechanisms Underlying Cell Type-Specific Vulnerability in Huntington’s Disease
-
批准号:10614595
-
项目类别:
-
资助金额:$54.29万
-
财政年份:2022
-
负责人:Myriam Heiman
-
依托单位:
Single-cell multi-region transcriptional and epigenomic dissection of VCID.
-
批准号:10532050
-
项目类别:
-
资助金额:$305.85万
-
财政年份:2022
-
负责人:Myriam Heiman
-
依托单位:
Reverse engineering zonation-specific and age-specific iPSC-derived cerebrovascular models based on transcriptomic profiling of the human brain
-
批准号:10321473
-
项目类别:
-
资助金额:$83.31万
-
财政年份:2021
-
负责人:Myriam Heiman
-
依托单位:
Single Cell Transcriptomic and Epigenomic Dissection of Opioid and Cocaine Responses in HIV
-
批准号:10672447
-
项目类别:
-
资助金额:$243.39万
-
财政年份:2021
-
负责人:Myriam Heiman
-
依托单位:
Determinants of cell type-specific vulnerability in Huntington's disease
-
批准号:10440179
-
项目类别:
-
资助金额:$36.5万
-
财政年份:2021
-
负责人:Myriam Heiman
-
依托单位:
Single Cell Transcriptomic and Epigenomic Dissection of Opioid and Cocaine Responses in HIV
-
批准号:10478928
-
项目类别:
-
资助金额:$244.79万
-
财政年份:2021
-
负责人:Myriam Heiman
-
依托单位:
Reverse engineering zonation-specific and age-specific iPSC-derived cerebrovascular models based on transcriptomic profiling of the human brain
-
批准号:10916740
-
项目类别:
-
资助金额:$45.78万
-
财政年份:2021
-
负责人:Myriam Heiman
-
依托单位:
Single Cell Transcriptomic and Epigenomic Dissection of Opioid and Cocaine Responses in HIV
-
批准号:10220620
-
项目类别:
-
资助金额:$246.19万
-
财政年份:2021
-
负责人:Myriam Heiman
-
依托单位:
Determinants of cell type-specific vulnerability in Huntington's disease
-
批准号:9418649
-
项目类别:
-
资助金额:$40.03万
-
财政年份:2017
-
负责人:Myriam Heiman
-
依托单位:
Determinants of cell type-specific vulnerability in Huntington's disease
-
批准号:9285159
-
项目类别:
-
资助金额:$40.03万
-
财政年份:2017
-
负责人:Myriam Heiman
-
依托单位:
Determinants of cell type-specific vulnerability in Huntington's disease
-
批准号:9910469
-
项目类别:
-
资助金额:$40.03万
-
财政年份:2017
-
负责人:Myriam Heiman
-
依托单位:
Development of SLIC, a methodology for synthetic lethal screening in the CNS
-
批准号:8889737
-
项目类别:
-
资助金额:$35.4万
-
财政年份:2013
-
负责人:Myriam Heiman
-
依托单位:
Development of SLIC, a methodology for synthetic lethal screening in the CNS
-
批准号:8639854
-
项目类别:
-
资助金额:$34.6万
-
财政年份:2013
-
负责人:Myriam Heiman
-
依托单位:
Development of SLIC, a methodology for synthetic lethal screening in the CNS
-
批准号:8742024
-
项目类别:
-
资助金额:$35.05万
-
财政年份:2013
-
负责人:Myriam Heiman
-
依托单位:
Animal Core
-
批准号:8150139
-
项目类别:
-
资助金额:$41.42万
-
财政年份:2010
-
负责人:Myriam Heiman
-
依托单位:
Cell Specific Analysis of Psychostimulant Drug Action
-
批准号:7254079
-
项目类别:
-
资助金额:$5.2万
-
财政年份:2006
-
负责人:Myriam Heiman
-
依托单位:
Cell Specific Analysis of Psychostimulant Drug Action
-
批准号:7113453
-
项目类别:
-
资助金额:$5.04万
-
财政年份:2006
-
负责人:Myriam Heiman
-
依托单位:
Animal Core
-
批准号:8328721
-
项目类别:
-
资助金额:$45.19万
-
财政年份:--
-
负责人:Myriam Heiman
-
依托单位:
Animal Core
-
批准号:8382719
-
项目类别:
-
资助金额:$32.9万
-
财政年份:--
-
负责人:Myriam Heiman
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: